NIH New Awards Are Down 34% in 2026. What 'Shell-Shocked' Researchers Should Actually Do Now

The numbers behind the anxiety in university labs this summer are no longer anecdotal. New NIH awards are down 34% in 2026 compared with prior years — a decline lawmakers attribute to new political-review layers across multiple agencies and to the Office of Extramural Research narrowing its funding opportunities. NSF is running months behind on award decisions. And a proposed Office of Management and Budget rewrite of the federal grant rules would, if finalized, let senior political appointees terminate awards mid-stream "if a Federal award does not effectuate program goals, Federal agency priorities, or the national interest" — with an effective date as early as October 1, 2026. As Northwestern stem-cell biologist Carole LaBonne put it, "Every scientist that I know at every institution across every state is pretty much shell-shocked right now."

We covered the mechanics of the rule itself in our analysis of the OMB 2 CFR Part 200 overhaul. This piece is about the harder question that no comment letter answers: given that the federal research-funding environment has already contracted and may stay contracted, what should researchers and institutions actually do between now and the fall? The honest answer is that waiting for the political fight to resolve is not a strategy. The contraction is already real in the award data, regardless of how the rulemaking ends.

What has actually changed — separating signal from noise

Three distinct developments are being conflated in most coverage, and untangling them is the first step to responding rationally.

1. The award slowdown is here now. The 34% drop in new NIH awards is not a forecast about the proposed rule — it is a measured decline that has already happened in 2026, driven by review delays and a narrowing of funding opportunity announcements. Researchers have faced grant denials and delays over the past 18 months. This is the part you cannot appeal; it is the current operating environment.

2. The proposed rule is not yet final. The OMB rewrite of 2 CFR Part 200 drew an extraordinary public response — well over a quarter of a million comments, all 50 Senate Democrats demanding rescission in a July 1 letter, and House appropriators questioning whether agencies are already applying the rule before the comment period even closed. Its most consequential provisions — political pre-issuance review replacing peer review, and discretionary mid-stream termination — take effect October 1 only if finalized as written. That outcome is genuinely uncertain and likely to be litigated.

3. The chilling effect is independent of both. Even where money is still flowing, the possibility of a six-month termination changes what gets proposed. As Northwestern pulmonary researcher Dr. Ravi Kalhan noted, "You can't study the prevention of diseases that take a lifetime to develop if the research program can get canceled in six months or a year." Long-horizon, prevention-oriented, and population-health research is disproportionately exposed.

The practical implication: a PI cannot control items 2 and 3, but can respond to item 1 today. That response is diversification.

A diversification playbook for PIs

For an individual investigator, the instinct to double down on more federal proposals is understandable and, in a 34%-contraction environment, mathematically insufficient. Spreading the same effort across a wider portfolio is the rational hedge.

• Move private foundations from afterthought to core. Disease-specific foundations, large health funders, and science philanthropies fund exactly the mechanistic and translational work NIH does — often faster, with lighter overhead expectations, and without the political-priority screen. The trade-off is smaller awards and shorter terms, which means running several foundation applications rather than one R01-sized bet. Total U.S. charitable giving remains enormous even amid softening individual donations, and health and science remain leading categories.
• Re-price your time toward earlier, smaller, faster mechanisms. Pilot awards, foundation seed grants, and industry-sponsored research agreements convert into preliminary data that strengthens the next federal proposal whenever the pipeline normalizes. In a slow-award environment, the value of keeping a lab staffed and generating data is higher than the value of a marginally more polished R01 that sits in a delayed queue.
• Treat SBIR/STTR as a genuine option if there is any translational angle. The small-business innovation programs are, notably, expanding in 2026 even as investigator-initiated research contracts — NSF restarted its program with a $250M allocation and a new $30M breakthrough tier, and NASA moved to a year-round rolling-appendix model. A faculty member with a spinout or a licensable technology has a non-dilutive channel that is moving in the opposite direction from R01s.
• Diversify the geography of your funding. State research initiatives, regional consortia, and international collaborations (where still permissible under the proposed international-collaboration restrictions) spread political risk across funders who do not share a single appropriations process.

What research offices and institutions should do

The institutional response matters more than any single lab's, because universities carry the fixed costs — staff, cores, facilities — that a lumpy award environment threatens.

• Build a bridge-funding facility now, not after a termination. The proposed rule's mid-stream termination provision, combined with the existing slowdown, makes short-term internal bridge funding a strategic necessity rather than a hardship exception. Institutions that pre-commit a bridge pool can retain trained staff through gaps; those that improvise lose people permanently.
• Stand up a foundation-relations and corporate-partnerships capacity. Most research offices are optimized for federal grant administration. The 2026 environment rewards institutions that can help faculty navigate foundation portals, industry-sponsored research contracting, and philanthropy — capabilities that have atrophied at federally dependent universities.
• Model your federal-dependency exposure explicitly. A department that derives 90% of its research revenue from NIH is running an undiversified portfolio in a contracting market. Quantifying that concentration — by department, by mechanism, by long-horizon vulnerability — turns a diffuse anxiety into a manageable risk register.
• Preserve the paper trail. If mid-stream terminations do arrive without a required showing of noncompliance or fraud, meticulous documentation of milestones, deliverables, and program alignment becomes the first line of defense in any appeal or litigation.

The strategic reframe

The uncomfortable truth is that the era of treating federal research funding as a stable, apolitical utility is over for the foreseeable future — not because any single rule is certain to survive, but because the variance has permanently increased. A 34% swing in new awards, the prospect of discretionary termination, and a review process subject to shifting political priorities all point to the same conclusion: funding concentration is now the primary risk, and diversification is the primary mitigation.

That is not a counsel of despair. Foundation philanthropy, SBIR/STTR, industry partnerships, and state programs are real, sizable, and in some cases growing. The researchers and institutions that come through this period strongest will be the ones who stopped treating those channels as supplementary and started treating them as core — before October, not after.

Casting a wider net for your research program? Granted helps investigators and institutions discover foundation, federal, SBIR, and state funding matched to their work — the diversification a single-agency search can't surface. Start a search across the full funding landscape.